Trials / Unknown
UnknownNCT03288597
Explore the Clinical Value of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in Neuroendocrine Neoplasms
A Prospective Exploration in the Clinical Value of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in Neuroendocrine Neoplasms
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 146 (estimated)
- Sponsor
- Peking University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
68Ga-DOTANOC and 18F-FDG PET/CT have important values in the staging and clinical treatment of neuroendocrine tumors. Retrospective studies suggest that the positivite rates and SUVmax of dual imaging associated with pathological findings and prognosis. The study was designed to confirm thet clinical values of dual imagings for neuroendocrine tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in NET | At the beginning of the treatment with SSA, after 6 months, 12 months, or chemotherapy, after 3 months or progression receive 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT |
| RADIATION | 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in NEC | At the beginning of the treatment with chemotherapy 4-6 cycles or progression receive 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT |
Timeline
- Start date
- 2017-09-01
- Primary completion
- 2018-09-01
- Completion
- 2020-09-01
- First posted
- 2017-09-20
- Last updated
- 2017-09-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03288597. Inclusion in this directory is not an endorsement.